Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Research synthesisModerate evidenceSmall effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across all 3 studies, Lactobacillus gasseri BNR17 showed beneficial small-sized effects on reducing abdominal pain in adults with functional constipation or irritable bowel syndrome (IBS). All studies were randomized controlled trials with statistically significant findings, but the total sample sizes were small (24–55 participants).

Studied populations: adults with functional constipation or irritable bowel syndrome (IBS-D or IBS with overweight)

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Doses were not consistently reported across studies, limiting dose-specific conclusions.

Generated Jun 11, 2026

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
The abstract does not report any adverse events, side effects, or safety findings. It only describes efficacy outcomes such as symptom improvement, health-related quality of life, colon transit time, and fecal microbiota changes.
from: A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lac

3 of 3 papersPopulation:

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.
- 2025-03-03
- RCT · n = 40
- Neurogastroenterology and motility 37(5)
- - Stefan Roos
  - Atti-La Dahlgren
  - Yu-Kang Mao
  - Anton Pallin
  - Andrew M Stanisz
  - Paul Forsythe
  - Wolfgang Kunze
  - Per M Hellström
- PubMed: 40033155
- DOI: 10.1111/nmo.70012
9 Insights on
- Reduced Abdominal Pain
- High evidence
Lactobacillus gasseri showed a significant reduction in abdominal pain, along with a correlation and tendency for an increased number of CSBM.
Effect
Beneficial
Effect size
Small
Significant
Yes
A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome
- 2020-09-30
- RCT · n = 24
- Journal of Clinical Biochemistry and Nutrition 62(2)
- - S. Shin
  - Yoon Mi Choi
  - W. Kim
  - S. Hong
  - Jong‐Min Park
  - Joohee Kim
  - O. Kwon
  - E. Lee
  - K. Hahm
- PubMed: 29610559
- DOI: 10.3164/jcbn.17-73
12 Insights on
- Reduced Abdominal Pain
- High evidence
- Rigorous Journal
Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17.
Effect
Beneficial
Effect size
Small
Significant
Yes
Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial
- 2017-12-12
- RCT · n = 55
- Food Science and Biotechnology 27(3)
- - J. Y. Kim
  - Y. Park
  - H. Lee
  - M. Park
  - O. Kwon
- PubMed: 30263811
- DOI: 10.1007/s10068-017-0296-7
3 Insights on
- Reduced Abdominal Pain
- High evidence
- Clinical
Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
2 × 5 × 10^9 CFU/day (high-dose, BNR-H)

Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.

A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome

Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial